Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
How would you approach a pre-viable pregnant patient in the second trimester with metastatic ovarian cancer and wants to keep the pregnancy?
Related Questions
For patients with ovarian cancer, do you order folate receptor-alpha testing at initial diagnosis, first recurrence, or first instance of platinum resistance?
When prescribing bevacizumab for high-risk primary ovarian cancer, do you use 15 mg/m2 q 21 days (per GOG-0218) or 7.5 mg/m2 q 21 days (per ICON7)?
How do you incorporate a KELIM score into your management of patients with ovarian cancer?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
How would you manage a patient with an incidental finding of 1 mm focus of high-grade serous carcinoma in the fallopian tube after TAHBSO was done for a benign broad ligament fibroid with negative pelvic washings?
What are your top takeaways in Gyn Cancers from ESMO 2024?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
